 |
|
Vaccine slows progression of skeletal muscle disorder
May 14, 2009Study in mice shows reduced levels of beta amyloid
A potential vaccine for Alzheimer's disease also has been shown in mice to slow the weakening of muscles associated with inclusion body myositis, a disorder that affects the elderly.
The finding brings new hope for IBM patients with weakness, inflammation or atrophy of muscles in their fingers, wrists, forearms or quadriceps. There is no cure for IBM, nor is there an effective treatment, according to the National Institutes of Health.
"The immunization wasn't a complete fix, but it significantly slowed the deterioration of motor function in our IBM mice," said Frank LaFerla, director of UC Irvine's Institute for Brain Aging and Dementia. "I hope our discovery leads to clinical trials and, eventually, a vaccine for people suffering from or at risk for IBM."
Study results appear Wednesday, May 13, in The Journal of Neuroscience.
LaFerla and assistant project scientist Masashi Kitazawa tested the vaccine on 1-year-old mice with high levels of a protein called beta amyloid in their skeletal muscle tissue - a characteristic feature of IBM.
After three months of treatment, the mice were producing antibodies against beta amyloid and had less of the protein in their muscles. Levels of oligomeric beta amyloid - a more toxic form - also were reduced.
"It appears the antibodies helped remove beta amyloid or blocked its accumulation in muscle cells so they could stay healthy longer," Kitazawa said.
Immunotherapy approaches such as vaccination are being extensively studied for Alzheimer's in humans. In that disease, beta amyloid accumulates in the brain and leads to the creation of senile plaques, one of two signature Alzheimer's lesions. Although immunotherapy has shown some benefit in human clinical trials, there are significant safety concerns. For example, about 6 percent of people develop encephalitis, or brain inflammation.
LaFerla thinks it's unlikely IBM patients would develop encephalitis: "With IBM, brain integrity is not compromised like it is with Alzheimer's. We should be cautious, but there's little reason to assume IBM patients would have the same problem."
UCI scientists Vitaly Vasilevko and David Cribbs also worked on this study, supported by the NIH.
University of California, Irvine
"The immunization wasn't a complete fix, but it significantly slowed the deterioration of motor function in our IBM mice," said Frank LaFerla, director of UC Irvine's Institute for Brain Aging and Dementia. "I hope our discovery leads to clinical trials and, eventually, a vaccine for people suffering from or at risk for IBM."
Study results appear Wednesday, May 13, in The Journal of Neuroscience.
LaFerla and assistant project scientist Masashi Kitazawa tested the vaccine on 1-year-old mice with high levels of a protein called beta amyloid in their skeletal muscle tissue - a characteristic feature of IBM.
After three months of treatment, the mice were producing antibodies against beta amyloid and had less of the protein in their muscles. Levels of oligomeric beta amyloid - a more toxic form - also were reduced.
"It appears the antibodies helped remove beta amyloid or blocked its accumulation in muscle cells so they could stay healthy longer," Kitazawa said.
Immunotherapy approaches such as vaccination are being extensively studied for Alzheimer's in humans. In that disease, beta amyloid accumulates in the brain and leads to the creation of senile plaques, one of two signature Alzheimer's lesions. Although immunotherapy has shown some benefit in human clinical trials, there are significant safety concerns. For example, about 6 percent of people develop encephalitis, or brain inflammation.
LaFerla thinks it's unlikely IBM patients would develop encephalitis: "With IBM, brain integrity is not compromised like it is with Alzheimer's. We should be cautious, but there's little reason to assume IBM patients would have the same problem."
UCI scientists Vitaly Vasilevko and David Cribbs also worked on this study, supported by the NIH.
University of California, Irvine
Beta Amyloid Current Events and Beta Amyloid News RSSUniversity Hospitals Case Medical Center to test gammaglobulin treatment for Alzheimer's disease
Researchers from the Memory and Cognition Center at University Hospitals Case Medical Center will begin testing an intriguing new approach to slowing down the progression of Alzheimer's Disease (AD) using Intravenous Immune Globulin (IGIV), also known as gammaglobulin.
Oxygen treatment hastens memory loss in Alzheimer's mice
A 65-year-old women goes into the hospital for routine hip surgery. Six months later, she develops memory loss and is later diagnosed with Alzheimer's Disease.
Phase 3 Alzheimer's drug increases toxic beta amyloid in the brain -- but still provides benefits
New insights into how a Phase III Alzheimer's drug might work were among the advances in potential therapies targeting two abnormal brain proteins - beta amyloid and phosphorylated tau - that were reported today at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna.
Brain imaging and proteins in spinal fluid may improve Alzheimer's prediction and diagnosis
Changes in the brain measured with MRI and PET scans, combined with memory tests and detection of risk proteins in body fluids, may lead to earlier and more accurate diagnosis of Alzheimer's.
Alzheimer's disease drug treats traumatic brain injury, report GUMC researchers
The destructive cellular pathways activated in Alzheimer's disease are also triggered following traumatic brain injury, say researchers from Georgetown University Medical Center (GUMC).
Caffeine reverses memory impairment in Alzheimer's mice
Coffee drinkers may have another reason to pour that extra cup. When aged mice bred to develop symptoms of Alzheimer's disease were given caffeine - the equivalent of five cups of coffee a day - their memory impairment was reversed.
Blood stem cell growth factor reverses memory decline in mice
A human growth factor that stimulates blood stem cells to proliferate in the bone marrow reverses memory impairment in mice genetically altered to develop Alzheimer's disease, researchers at the University of South Florida and James A. Haley Hospital found.
Popular Alzheimer's theory may be false trail
The idea that anti-inflammatory drugs might protect people struggling with dementia from Alzheimer's disease has received a blow with the online release of a study of human brain tissue in Acta Neuropathologica.
Vitamin B3 reduces Alzheimer's symptoms, lesions
An over-the-counter vitamin in high doses prevented memory loss in mice with Alzheimer's disease, and UC Irvine scientists now are conducting a clinical trial to determine its effect in humans.
Common epilepsy drug could prevent and treat Alzheimer's disease
The team led by UBC Psychiatry Prof. Weihong Song, who is also the Jack Brown and Family Professor and Chair in Alzheimer's Disease at UBC, found that if Valproic Acid (VPA) is used as a treatment in early stages of AD memory deficit is reversed.
More Beta Amyloid Current Events and Beta Amyloid News Articles
 |
Alzheimer's Disease: Cellular and Molecular Aspects of Amyloid beta (Subcellular Biochemistry) by Robin Harris (Editor), Falk Fahrenholz (Editor) Preface: To understand Alzheimer?s disease (AD) is one of the major thrusts of present-day clinical research, strongly supported by more fundamental cellular, biochemical, immunological and structural studies. It is these latter that receive attention within this book. This compilation of 20 chapters indicates the diversity of work currently in progress and summarizes the current state of knowledge. Experienced authors who are scientifically active in their fields of study have been selected as contributors to this book, in an attempt to present a reasonably complete survey of the field. Inevitably, some exciting topics for one reason or another have not been included, for which we can only apologize. Standardization of terminology is often a problem in science, not least... |
![[beta]-amyloid Peptide (1-42), Human, Oncogene - Size 250 Ug - Model Pp69--25mg - Each (.25 Mg)](http://ecx.images-amazon.com/images/I/31Y1NF0J0EL._SL160_.gif) |
[beta]-amyloid Peptide (1-42), Human, Oncogene - Size 250 Ug - Model Pp69--25mg - Each (.25 Mg) by Oncogene [beta]-Amyloid Peptide (1-42), Human, Oncogene - Size 250 ug - Model PP69--25MG - Each (.25 MG) : Lyophilized.Synthetic peptide corresponding to amino acids 1-42 of the processed human amyloid peptide. Supplied in a form that is not neurotoxic prior to preincubation. The level of toxicity has recently been shown to correlate to the extent of beta sheet structure. Reconstitute with degassed HPLC grade deionized water. Purity: >95% by HPLC. FW: 4 kDa. |
 |
Amyloid Proteins: The Beta Sheet Conformation and Disease by Jean D. Sipe (Editor) A first-stop reference on proteins associated with amyloidosis. This book is the first to present a systematic overview of all known fibril-forming proteins, including their biochemical characteristics and pathophysiology. It considers the clinically recognized amyloid proteins that are known to be associated with the amyloid protein folding disorders, dealing with their common structural and thermodynamic features that lead to amyloid fibril formation and disease. Emphasis is on the thermodynamics of protein folding, the structure and physiologic effects of common oligomeric and subfibrillar intermediates and the influence of the extracellular matrix and cellular trafficking and metabolism on the genesis and catabolism of beta pleated sheet proteins. The chapters on... |
|
Nerve link: Alzheimer's suspect shows up in glaucoma.(This Week)(amyloid beta-protein): An article from: Science News by N. Seppa (Author) This digital document is an article from Science News, published by Thomson Gale on August 11, 2007. The length of the article is 483 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Nerve link: Alzheimer's suspect shows up in glaucoma.(This Week)(amyloid beta-protein) Author: N. Seppa Publication: Science News (Magazine/Journal) Date: August 11, 2007 Publisher: Thomson Gale Volume: 172 Issue: 6 Page: 84(2) Distributed by Thomson... | |
|
The Structure and Function of Alzheimer's Amyloid Beta Proteins (Medical Intelligence Unit) by David Schubert (Editor) | |
|
Alzheimer's allele related to early beta-amyloid deposition.(Adult Psychiatry): An article from: Clinical Psychiatry News by Mary Ann Moon (Author) This digital document is an article from Clinical Psychiatry News, published by Thomson Gale on October 1, 2006. The length of the article is 559 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Alzheimer's allele related to early beta-amyloid deposition.(Adult Psychiatry) Author: Mary Ann Moon Publication: Clinical Psychiatry News (Magazine/Journal) Date: October 1, 2006 Publisher: Thomson Gale Volume: 34 Issue: 10 Page: 31(1) Distributed by Thomson... | |
|
Beta amyloid: the peptide that kills from both the outside and inside to produce Alzheimer's disease. (Collegiate Communications--Undergraduate).(Brief ... of the North Dakota Academy of Science by Jason Spah (Author), Katherine Splichal (Author), Kali Wilson (Author), Garl K. Rieke (Author) This digital document is an article from Proceedings of the North Dakota Academy of Science, published by North Dakota Academy of Science on April 1, 2000. The length of the article is 897 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Beta amyloid: the peptide that kills from both the outside and inside to produce Alzheimer's disease. (Collegiate Communications--Undergraduate).(Brief Article) Author: Jason Spah Publication: Proceedings of the North Dakota Academy of Science (Refereed) Date: April 1, 2000 Publisher: North Dakota Academy of Science Page:... | |
|
Brain sabotage: Alzheimer's protein may spawn miniseizures.(This Week)(Amyloid beta-protein): An article from: Science News by N. Seppa (Author) This digital document is an article from Science News, published by Thomson Gale on September 15, 2007. The length of the article is 536 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Brain sabotage: Alzheimer's protein may spawn miniseizures.(This Week)(Amyloid beta-protein) Author: N. Seppa Publication: Science News (Magazine/Journal) Date: September 15, 2007 Publisher: Thomson Gale Volume: 172 Issue: 11 Page: 165(2) Distributed by Thomson... | |
|
Biochemical and Biophysical Research Communications. Volume 151. Fine Mapping of an Alzheimer Disease Associated Gene Encoding beta-Amyloid Protein by Jenkins et al. etc. 1988 by Jenkins et al (Author) | |
|
|
[beta]-amyloid Peptide (1-40, Gln22), Human, Oncogene - Size 500 Ug - Model Pp68--5mg - Each (1 Mg) by Oncogene [beta]-Amyloid Peptide (1-40, Gln22), Human, Oncogene - Size 500 ug - Model PP68--5MG - Each (1 MG) : Lyophilized.Synthetic peptide corresponding to amino acids 1-40 of the processed human amyloid peptide with a substitution of Gln22. Supplied in a form that is not neurotoxic prior to preincubation. The level of toxicity has recently been shown to correlate to the extent of beta sheet structure. Reconstitute with degassed HPLC grade deionized water. Purity: >99% by HPLC. FW: 4 kDa. |
| © 2009 BrightSurf.com |